Below is Validea's guru fundamental report for EQUIFAX INC (EFX). Of the 22 guru strategies we follow, EFX rates highest using our P/B Growth Investor model based on the published strategy of ...

Its lead candidate efruxifermin (EFX) is currently in Phase 3 trials and aims to address the underlying metabolic dysfunctions associated with these conditions. The company is heavily reliant on ...

39% of patients in the 50mg EFX group demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, a significant finding with a p-value of 0.009 compared to placebo. Data suggests ...